189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

Autor:	B. Wehler, Christian Grohé, J. Topsch, T. Wehler, A. Ehrlich, H. Atmaca-Dirik, Christian Schulz
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry Afatinib Phase IV Trial First line treatment Egfr mutation Internal medicine medicine Osimertinib In patient business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 16:S800-S801
ISSN:	1556-0864
DOI:	10.1016/s1556-0864(21)02031-1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::65ccf513c776abda366b941f41cabad0 https://doi.org/10.1016/s1556-0864(21)02031-1 Zobrazit plný text záznamu